Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 17,687 |
|
|||||
| News | - | ||||||
| Day High | 1.41 | Low High |
|||||
| Day Low | 1.39 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Medicinova Inc | MNOV | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.40 | 16:02:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.40 | 1.39 | 1.41 | 1.40 | 1.40 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 123 | 17,687 | $ 1.40 | $ 24,724 | - | 1.26 - 2.66 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 1,060 | $ 1.39 | USD |
Medicinova Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 68.17M | 49.05M | - | 1M | -8.57M | -0.17 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Medicinova News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNOV Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.60 | 1.6399 | 1.39 | 1.50 | 32,144 | -0.20 | -12.50% |
| 1 Month | 1.45 | 1.6399 | 1.36 | 1.47 | 52,298 | -0.05 | -3.45% |
| 3 Months | 1.49 | 1.6399 | 1.26 | 1.40 | 53,464 | -0.09 | -6.04% |
| 6 Months | 2.01 | 2.16 | 1.26 | 1.75 | 84,603 | -0.61 | -30.35% |
| 1 Year | 2.25 | 2.66 | 1.26 | 1.84 | 52,026 | -0.85 | -37.78% |
| 3 Years | 4.48 | 5.09 | 1.26 | 3.58 | 168,526 | -3.08 | -68.75% |
| 5 Years | 9.57 | 13.37 | 1.26 | 6.64 | 286,002 | -8.17 | -85.37% |
Medicinova Description
| MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments. |
